Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

BCR gene fused ABL kinase is the critical driving force for the Philadelphia Chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) and has been extensively explored as a drug target. With a structure-based drug design approach we have discovered a novel inhibitor CHMFL-074, that potently inhibits...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Liu, Feiyang, Wang, Beilei, Wang, Qiang, Qi, Ziping, Chen, Cheng, Kong, Lu-Lu, Chen, Ji-Yun, Liu, Xiaochuan, Wang, Aoli, Hu, Chen, Wang, Wenchao, Wang, Huiping, Wu, Fan, Ruan, Yanjie, Qi, Shuang, Liu, Juan, Zou, Fengming, Hu, Zhenquan, Wang, Wei, Wang, Li, Zhang, Shanchun, Yun, Cai-Hong, Zhai, Zhimin, Liu, Jing, Liu, Qingsong
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216742/
https://ncbi.nlm.nih.gov/pubmed/27322145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10037
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares